Envista’s (NVST) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Envista (NYSE:NVST) in a research note released on Thursday,Benzinga reports.

Several other analysts also recently commented on the stock. Piper Sandler increased their price objective on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Mizuho started coverage on shares of Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target for the company. Wells Fargo & Company upped their price objective on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research report on Thursday, February 6th. Jefferies Financial Group lifted their target price on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Finally, Morgan Stanley upped their price target on Envista from $19.00 to $20.00 and gave the company an “equal weight” rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $20.38.

Envista Price Performance

Shares of NYSE NVST opened at $18.47 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The company has a 50 day simple moving average of $20.22 and a two-hundred day simple moving average of $19.69. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $23.00. The company has a market capitalization of $3.18 billion, a price-to-earnings ratio of -2.85, a P/E/G ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Analysts expect that Envista will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Several institutional investors have recently made changes to their positions in the business. Ariel Investments LLC boosted its stake in shares of Envista by 6.2% during the 4th quarter. Ariel Investments LLC now owns 12,059,624 shares of the company’s stock worth $232,630,000 after acquiring an additional 699,625 shares during the last quarter. Nuance Investments LLC lifted its position in Envista by 4.4% during the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock valued at $145,168,000 after purchasing an additional 308,221 shares in the last quarter. Franklin Resources Inc. grew its holdings in Envista by 72.6% during the fourth quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after purchasing an additional 2,882,844 shares during the period. Dimensional Fund Advisors LP increased its position in Envista by 19.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock worth $130,440,000 after buying an additional 1,089,923 shares in the last quarter. Finally, Gates Capital Management Inc. raised its stake in shares of Envista by 15.1% in the fourth quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company’s stock worth $90,550,000 after buying an additional 615,577 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.